Ruxolitinib in polycythaemia vera: Hint of non-quantifiable added benefit
Ruxolitinib (trade name: Jakavi) has been approved since March 2015 for the treatment of adults with polycythaemia vera, a rare disease of the bone marrow. It can be used when the drug hydroxyurea is ineffective or not tolerated. ...
Aug 7, 2015
0
6